Delta Dental of New Jersey will invest $5 million in biotechnology company C3 Jian, which is developing a new drug that targets caries, according to an njbiz.com story.
Los Angeles-based C3 Jian has raised $60.5 million to support continued clinical development of the company's lead product, C16G2, a proprietary peptide-based antimicrobial drug specifically targeting Streptococcus mutans, a bacterium responsible for dental caries.
The company recently began a phase II clinical trial to study C16G2 formulated as a mouth rinse and a gel for both dental tray and toothbrush applications.
